6943-33-5

Basic information

• Product Name: 5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE
• Synonyms: 5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE
• CAS NO: 6943-33-5
• Molecular Formula: C₁₀H₉BrN₂O₂
• Molecular Weight: 269.09
• Mol File: 6943-33-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.559g/cm³
• Refractive Index: 1.581
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE(6943-33-5)
• EPA Substance Registry System: 5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE(6943-33-5)

Safety Data

• Hazardous Substances Data: 6943-33-5(Hazardous Substances Data)

Usage

General Description

5-(3-Bromo-phenyl)-5-methyl-imidazolidine-2,4-dione is a chemical compound with the molecular formula C10H10BrN2O2. It is an imidazolidine-2,4-dione derivative with a 3-bromo-phenyl substituent and a methyl group at the 5-position of the imidazolidine ring. 5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE is commonly used in organic synthesis and medicinal chemistry research. It may have potential pharmacological properties and could be used as a building block for the synthesis of other biologically active molecules. As a heterocyclic compound, it may exhibit unique chemical and biological properties, making it of interest to researchers in various fields of science and technology.

InChI:InChI=1/C10H9BrN2O2/c1-10(8(14)12-9(15)13-10)6-3-2-4-7(11)5-6/h2-5H,1H3,(H2,12,13,14,15)

Upstream product

• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 506-87-6 ammonium carbonate 
• 151-50-8 potassium cyanide 

Downstream Products

• 1262858-65-0 (RS)-2-amino-2-(3-bromo-phenyl)-propionic acid hydrochloride 
• 1372806-23-9 C₁₁H₁₁BrN₂OS 
• 856877-35-5 C₁₁H₁₂BrN₃O 
• 856884-79-2 C₁₇H₁₆ClN₃O 
• 1372806-08-0 C₁₁H₁₁BrN₂O₂ 
• 1183013-69-5 (RS)-2-amino-2-(3-bromo-phenyl)-propan-1-ol 
• 1262858-67-2 rac-5-(3-bromophenyl)-5-methylmorpholin-3-one 
• 1262858-69-4 rac-5-(3-bromophenyl)-5-methyl-5,6-dihydro-2H-[1,4]oxazin-3-ylamine 
• 1183581-39-6 (RS)-2-amino-2-(3-bromo-phenyl)-propionic acid methyl ester 
• 1266784-81-9 (RS)-3-(3-Bromo-phenyl)-5-methoxy-3-methyl-3,6-dihydro-2H [1,4]oxazine 
• 1266784-96-6 (RS)-[bis-(4-methoxy-phenyl)-phenyl-methyl]-[5-(3-bromo-phenyl)-5-methyl-5,6-dihydro-2H-[1,4]oxazin-3-yl]-amine 
• 1386997-98-3 (RS)-(3-chloro-benzyl)-[3-(5-methoxy-3-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-phenyl]-amine 
• 1071454-35-7 5-{3-[3-(2-methoxy-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-phenyl}-5-methyl-imidazolidine-2,4-dione 
• 916770-75-7 3-[4-(3-bromo-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-ylmethyl]-benzoic acid methyl ester 

Relevant articles and documents

Identification and Profiling of Hydantoins - A Novel Class of Potent Antimycobacterial DprE1 Inhibitors

Tuberculosis is the leading cause of death worldwide from infectious diseases. With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action. Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-β-d-ribofuranose 2-oxidase (DprE1). In this study, we have prepared a library of more than a 100 compounds and evaluated them for their biological and physicochemical properties. The series is characterized by high enzymatic and whole-cell activity, low cytotoxicity, and a good overall physicochemical profile. In addition, we show that the series acts via reversible inhibition of the DprE1 enzyme. Overall, the novel compound family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.

5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS

The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

From an initial lead 1, a structure-based design approach led to identification of a novel, high-affinity iminohydantoin BACE1 inhibitor that lowers CNS-derived Aβ following oral administration to rats. Herein we report SAR development in the S3 and F′ subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for the optimized compound.